GOVERNMENT OF THE PEOPLE'S REPUBLIC OF BANGLADESH
MINISTRY OF HEALTH & FAMILY WELFARE
DIRECTORATE GENERAL OF DRUG ADMINISTRATION
OUSHAD BHABAN, MOHAKHALI
DHAKA-1212, BANGLADESH
www.dgda.gov.bd

Ref. WHO TRS, NO. 927, 2005, ANNEX-1

Date: 14/05/2018

The Guideline on Non-clinical Evaluation of Vaccine

In Bangladesh DGDA is functioning as National Regulatory Authority.
As a competent medicine regulatory authority it gives marketing authorization of vaccines for the purpose of marketing or distribution after evaluation of its safety, efficacy and quality.

In General vaccines are distinguished from other drugs by being derived from living organisms (ranging from normal or genetically modified microorganisms to humans), and frequently have a complex molecular structure.
They require special quality considerations because of the biological nature of a) the starting material, and/or b) the manufacturing process, and/or c) the test methods needed to characterize batch to batches of the product.

So guidelines are needed to review the submitted documents/ dossier of vaccine product properly and effectively.

In these purpose WHO TRS, No. 927, 2005 Annex-1, on "WHO Guideline on Nonclinical evaluation of Vaccine" is very extensive guidelines which covered all the non-clinical aspect and issues of reviewing application and documentation of marketing authorization.

So this guidelines (page: 31-63) is adopted for the purpose of review in DGDA from the date give below and valid up to next office order.

Date of Adoption	:	14.05.2018
Date of Training	:	28.11.2018
Date of Effective	:	29.11.2018
Date of Review	:	28.11.2023

Major General Md. Mustafizur Rahman
Director General
Directorate General of Drug Administration
&
Licensing Authority (Drugs)